𝔖 Bobbio Scriptorium
✦   LIBER   ✦

ChemInform Abstract: Discovery of GSK345931A: An EP1 Receptor Antagonist with Efficacy in Preclinical Models of Inflammatory Pain.

✍ Scribed by Adrian Hall; et al. et al.

Publisher
John Wiley and Sons
Year
2009
Weight
18 KB
Volume
40
Category
Article
ISSN
0931-7597

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.

📜 SIMILAR VOLUMES

ChemInform Abstract: Discovery of Sodium
ChemInform Abstract: Discovery of Sodium 6-[(5-Chloro-2-{ [(4-chloro-2-fluorophenyl)methyl]oxy}phenyl)methyl] -2-pyridinecarboxylate (GSK269984A) (VIIb) an EP1 Receptor Antagonist for the Treatment of Inflammatory Pain.
✍ Adrian Hall; et al. et al. 📂 Article 📅 2009 🏛 John Wiley and Sons ⚖ 33 KB

## Abstract ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable v

ChemInform Abstract: Discovery of an Imi
ChemInform Abstract: Discovery of an Imidazopyridine-Containing 1,4-Benzodiazepine Nonpeptide Vitronectin Receptor (αvβ3) Antagonist with Efficacy in a Restenosis Model.
✍ Richard M. Keenan; M. Amparo Lago; William H. Miller; ET AL. ET AL. 📂 Article 📅 2010 🏛 John Wiley and Sons ⚖ 32 KB 👁 1 views

Discovery of an Imidazopyridine-Containing 1,4-Benzodiazepine Nonpeptide Vitronectin Receptor (αvβ3) Antagonist with Efficacy in a Restenosis Model. -Among a variety of title compounds of type (I) and (II) the derivative (II) has sufficient potency and in vivo pharmacokinetics for demonstration of e